| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gregory T Carter, Vivian Ugald. Medical marijuana: emerging applications for the management of neurologic disorders. Physical medicine and rehabilitation clinics of North America. vol 15. issue 4. 2004-12-23. PMID:15458761. |
marijuana contains over 60 different types of cannabinoids, which are its medicinally active ingredients. |
2004-12-23 |
2023-08-12 |
Not clear |
| Daniele Piomell. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. vol 47 Suppl 1. 2004-12-20. PMID:15464150. |
marijuana use may lead to adaptive changes in endocannabinoid signaling, and these changes might contribute to effects of marijuana as well as to the establishment of marijuana dependence. |
2004-12-20 |
2023-08-12 |
Not clear |
| Daniele Piomell. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. vol 47 Suppl 1. 2004-12-20. PMID:15464150. |
in addition, i review recent progress on the development of pharmacological agents that interfere with endocannabinoid deactivation and discuss their potential utility in the treatment of marijuana dependence and other aspects of drug abuse. |
2004-12-20 |
2023-08-12 |
Not clear |
| J H Allen, G M de Moore, R Heddle, J C Twart. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. vol 53. issue 11. 2004-12-02. PMID:15479672. |
cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. |
2004-12-02 |
2023-08-12 |
Not clear |
| Adèle Thomas, Ruth A Ross, Bijali Saha, Anu Mahadevan, Raj K Razdan, Roger G Pertwe. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. European journal of pharmacology. vol 487. issue 1-3. 2004-11-24. PMID:15033394. |
previous experiments with the mouse vas deferens have shown that cannabidiol produces surmountable antagonism of cannabinoid cb(1) receptor agonists at concentrations well below those at which it binds to cannabinoid cb(1) receptors and antagonizes alpha(1)-adrenoceptor agonists insurmountably. |
2004-11-24 |
2023-08-12 |
mouse |
| Adèle Thomas, Ruth A Ross, Bijali Saha, Anu Mahadevan, Raj K Razdan, Roger G Pertwe. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. European journal of pharmacology. vol 487. issue 1-3. 2004-11-24. PMID:15033394. |
we have now found that subtle changes in the structure of cannabidiol markedly influence its ability to produce each of these effects, suggesting the presence of specific pharmacological targets for this non-psychoactive cannabinoid. |
2004-11-24 |
2023-08-12 |
mouse |
| Adèle Thomas, Ruth A Ross, Bijali Saha, Anu Mahadevan, Raj K Razdan, Roger G Pertwe. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. European journal of pharmacology. vol 487. issue 1-3. 2004-11-24. PMID:15033394. |
however, it produced this antagonism with a potency that matched its cannabinoid cb(1) receptor affinity, suggesting that, unlike cannabidiol, it is a competitive cannabinoid cb(1) receptor antagonist. |
2004-11-24 |
2023-08-12 |
mouse |
| Catherine A Newton, Tangying Lu, Stanley J Nazian, Izabella Perkins, Herman Friedman, Thomas W Klei. The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2. Journal of leukocyte biology. vol 76. issue 4. 2004-11-09. PMID:15258190. |
t helper cell type 1 (th1)-polarizing cytokines are induced by legionella pneumophila infection and are suppressed by pretreatment with marijuana cannabinoids (cb). |
2004-11-09 |
2023-08-12 |
mouse |
| Dorothea Gadzicki, Kirsten R Müller-Vahl, Daniela Heller, Sebastian Ossege, Markus M Nöthen, Johannes Hebebrand, Manfred Stuhrman. Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 127B. issue 1. 2004-11-02. PMID:15108190. |
involvement of the central cannabinoid (cb1) system is suggested because of therapeutic effects of marijuana (cannabis sativa l.) consumption and delta(9)-tetrahydrocannabinol (-thc) treatment in ts patients. |
2004-11-02 |
2023-08-12 |
Not clear |
| Albert D Fraser, David Wort. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV. Forensic science international. vol 143. issue 2-3. 2004-11-01. PMID:15240035. |
further urinary cannabinoid excretion studies are needed to assess whether 11-oh-delta9-thc analyses have a role when assessing previous marijuana or hashish use in chronic users whose urine specimens remain positive for delta9-thc-cooh for an extended period of time after last drug use. |
2004-11-01 |
2023-08-12 |
human |
| Paul F Smit. Medicinal cannabis extracts for the treatment of multiple sclerosis. Current opinion in investigational drugs (London, England : 2000). vol 5. issue 7. 2004-10-18. PMID:15298068. |
however, in the last two years, results of several placebo-controlled clinical trials of orally administered compounds have been published, and these cast doubt on the efficacy of delta9-tetrahydrocannabinol (delta9-thc) in objectively reducing spasticity in ms. by contrast, it has been claimed that sublingually administered cannabis extracts that contain approximately equal concentrations of delta9-thc and cannabidiol, a natural cannabinoid that does not act on the cb1 receptor, can produce a statistically and clinically significant reduction in spasticity, although this claim has yet to be thoroughly validated. |
2004-10-18 |
2023-08-12 |
Not clear |
| Luciano De Petrocellis, Maria Grazia Cascio, Vincenzo Di Marz. The endocannabinoid system: a general view and latest additions. British journal of pharmacology. vol 141. issue 5. 2004-10-14. PMID:14744801. |
after the discovery, in the early 1990s, of specific g-protein-coupled receptors for marijuana's psychoactive principle delta(9)-tetrahydrocannabinol, the cannabinoid receptors, and of their endogenous agonists, the endocannabinoids, a decade of investigations has greatly enlarged our understanding of this altogether new signalling system. |
2004-10-14 |
2023-08-12 |
Not clear |
| P Derkinderen, E Valjent, F Darcel, P Damier, J-A Giraul. [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. Revue neurologique. vol 160. issue 6-7. 2004-10-12. PMID:15247852. |
[cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. |
2004-10-12 |
2023-08-12 |
Not clear |
| Vincenzo Di Marzo, Maurizio Bifulco, Luciano De Petrocelli. The endocannabinoid system and its therapeutic exploitation. Nature reviews. Drug discovery. vol 3. issue 9. 2004-09-30. PMID:15340387. |
the term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in cannabis, delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. |
2004-09-30 |
2023-08-12 |
Not clear |
| Yoonkyung Do, Robert J McKallip, Mitzi Nagarkatti, Prakash S Nagarkatt. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. Journal of immunology (Baltimore, Md. : 1950). vol 173. issue 4. 2004-09-28. PMID:15294950. |
addition of delta(9)-tetrahydrocannabinol (thc), a major psychoactive component found in marijuana or anandamide, an endogenous cannabinoid, to dc cultures induced apoptosis in dcs. |
2004-09-28 |
2023-08-12 |
mouse |
| José M Oliva, Sergio Ortiz, Tomás Palomo, Jorge Manzanare. Spontaneous cannabinoid withdrawal produces a differential time-related responsiveness in cannabinoid CB1 receptor gene expression in the mouse brain. Journal of psychopharmacology (Oxford, England). vol 18. issue 1. 2004-08-30. PMID:15107186. |
these findings further suggest a time and regional differential role for cannabinoid receptors in short- and long-term neuroadaptations that occur after exposure to cannabis derivatives. |
2004-08-30 |
2023-08-12 |
mouse |
| Dirk W Lachenmeier, Lars Kroener, Frank Musshoff, Burkhard Made. Determination of cannabinoids in hemp food products by use of headspace solid-phase microextraction and gas chromatography-mass spectrometry. Analytical and bioanalytical chemistry. vol 378. issue 1. 2004-08-26. PMID:14598006. |
cannabinoids were detected in all of the samples and it was possible to differentiate between drug-type and fiber-type cannabis sativa l. in comparison with other studies relatively low thc concentrations between 0.01 and 15.53 mg kg(-1) were determined. |
2004-08-26 |
2023-08-12 |
Not clear |
| B Kraft, H G Kres. [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz (Berlin, Germany). vol 18. issue 3. 2004-08-18. PMID:15221424. |
the medical use of cannabis or cannabinoid compounds is controversial. |
2004-08-18 |
2023-08-12 |
mouse |
| Boram Park, John M McPartland, Michelle Glas. Cannabis, cannabinoids and reproduction. Prostaglandins, leukotrienes, and essential fatty acids. vol 70. issue 2. 2004-08-17. PMID:14683692. |
cannabis, cannabinoids and reproduction. |
2004-08-17 |
2023-08-12 |
Not clear |
| Boram Park, John M McPartland, Michelle Glas. Cannabis, cannabinoids and reproduction. Prostaglandins, leukotrienes, and essential fatty acids. vol 70. issue 2. 2004-08-17. PMID:14683692. |
the purpose of this review is therefore twofold, to examine the impact that cannabis use may have on fertility and reproduction, and to review the potential role of the endocannabinoid system in hormonal regulation, embryo implantation and maintenance of pregnancy. |
2004-08-17 |
2023-08-12 |
Not clear |